This website is intended for UK healthcare professionals only. Not a UK healthcare professional? Click here.

Prescribing Information and Adverse Event Reporting (links to external website):

NUSTENDI®

NILEMDO®

Role of bempedoic acid in the management of CV risk reduction in type 2 diabetes and elevated LDL-C and real-world experience

In this video, Dr. Elnaggar emphasised the importance of lipid management in mitigating CV risk for patients with type 2 diabetes and elevated LDL-C

Dr. Mohamed Elnagger

Date: 01/06/2026

5 mins

Speaker bios

Doctor Mohamed Elnagger
Doctor Mohamed Elnagger

Consultant Endocrinologist, Lipidologist and Clinical Lead for Lipid Services, University Hospitals of Morecambe Bay NHS Foundation Trust

Dr. Elnaggar is currently also serving as Clinical Lipid lead of South Cumbria and Lancashire. He has been involved in Lipidology teaching and research as a lecturer at the Alexandria Faculty of Medicine. He is currently acting as an honorary lecturer at Lancaster University. Dr. Elnaggar has a great passion for education and teaching and has been involved in numerous national and international conferences and speaker events. He is also involved in several lipid-related trials and is invested in research involving newer lipid-lowering therapies.

Read More

Optimising lipid management in type 2 diabetes and elevated LDL-C and real-world experience Previous Why should primary prevention lipid management be prioritised? Next

Abbreviations

CV, cardiovascular; LLT, lipid-lowering therapy; NHS, National Health Service.

Job code: UK/BIL/01/26/0001|Date of preparation: June 2026

Job code: UK/BIL/01/26/0003|Date of preparation: April 2026

All rights reserved. © Daiichi Sankyo UK Limited. Company No: 01998736

You are now leaving this website

Please note that our terms of use (especially those mentioned under "Terms and Conditions") are no longer valid as soon as you click on the "Continue" button. As we do not have any influence on linked websites, we assume no liability for their content or use. If you would like to return to our website, please click the "Return" button.

Job code: UK/BIL/11/24/0015 | Date of preparation: February 2025

This is a Daiichi Sankyo site intended for UK healthcare professionals (HCPs) and other relevant decision makers,* where you can find promotional information about Daiichi Sankyo products and professional resources.

So that we can provide you with the most appropriate information, please choose one of the following options:

I am a UK healthcare professional

This website contains promotional information intended for UK healthcare professionals and other relevant decision makers only.

Confirm
I am a member of the public

This website provides members of the UK public with details about Daiichi Sankyo and its medicines. For further information about your health or medicines please consult your doctor, nurse or pharmacist.

Confirm

*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply, or use of any medicine but who are not healthcare professionals.

Job code: UK/BIL/11/24/0002 | Date of preparation: February 2025

All rights reserved. © Daiichi Sankyo UK Limited. Company No: 01998736